Jadenu
Jadenu is an originator product from Novartis Pharma Schweiz AG and is listed on the FOPH Specialities List. Swiss mandatory health insurance therefore reimburses it within the authorised indication. The public price ranges from CHF 221.40 to CHF 1'422.45 depending on the pack; the patient co-payment is 40 per cent plus the deductible.
Core data
- Authorisation holder
- Novartis Pharma Schweiz AG
- ATC code
- V03AC03
- IT group
- 06.99 Varia
- Active substances
- Deferasiroxum
- Preparation type
- Originator product
- On the SL since
- 01/04/2017
- Last price change
- 01/12/2024
- Co-payment
- 40%
Prices per pack
The ex-factory price is the authorisation holder's price; the public price adds the distribution share and VAT. Both are FOPH maximum prices: nothing above them may be charged.
| Dosage form | Pack size | Ex-factory price | Public price | Valid from | Cat. | GTIN |
|---|---|---|---|---|---|---|
| Filmtabl 90 mg | 30 Stk | CHF 191.20 | CHF 221.40 | 01/11/2017 | B | 7680658670010 |
| Filmtabl 90 mg | 90 Stk | CHF 487.57 | CHF 539.15 | 01/04/2017 | B | 7680658670027 |
| Filmtabl 180 mg | 30 Stk | CHF 313.58 | CHF 352.65 | 01/11/2017 | B | 7680658670034 |
| Filmtabl 180 mg | 90 Stk | CHF 799.62 | CHF 873.75 | 01/04/2017 | B | 7680658670041 |
| Filmtabl 360 mg | 30 Stk | CHF 514.27 | CHF 567.80 | 01/04/2017 | B | 7680658670058 |
| Filmtabl 360 mg | 90 Stk | CHF 1'311.37 | CHF 1'422.45 | 01/04/2017 | B | 7680658670065 |
Limitation
This preparation is reimbursed only under the conditions below. The text is the binding FOPH wording; outside those conditions basic insurance does not pay.
The FOPH publishes limitation texts in German, French and Italian only. The German wording is reproduced verbatim below.
- als Erstlinientherapie zur Behandlung der chronischen Eisenüberladung auf Grund häufiger Transfusionen bei Patienten mit Beta-Thalassämia major.
- für die Behandlung von weiteren chronischen, transfusionsbedingten Eisenüberladungen, wenn eine Deferoxamin-Therapie kontraindiziert oder unangemessen ist.
- für die Behandlung der chronischen Eisenüberladung bei Patienten mit nicht transfusionsabhängigen Thalassämie-Syndromen im Alter von 10 Jahren und älter, wenn eine Deferoxamin-Therapie kontraindiziert oder unangemessen ist.
Therapien, die vor der Einführung der angepassten Limitierung (1. Juni 2023) begonnen wurden, werden weiterhin vergütet, sofern es sich um eine Behandlung entsprechend der von Swissmedic zugelassenen Indikation handelt.
More preparations in this group
FAQ
Is Jadenu covered by Swiss health insurance?
Yes, but only under conditions. Jadenu is on the Specialities List with a limitation: basic insurance reimburses it only when the conditions in the limitation text are met, in some cases only after the insurer has granted cost approval.
What does Jadenu cost in Switzerland?
The public price is the maximum price set by the FOPH and for Jadenu ranges from CHF 221.40 to CHF 1'422.45 per pack. The ex-factory price ranges from CHF 191.20 to CHF 1'311.37. Pharmacies may not charge more, but may charge less.
Market access
Do you need your product on the Specialities List?
Questions about SL listing, prices or limitations? Contact Swiss Reimbursement.
- Independent directory
- Official FOPH data
- Website in eight languages